EDG-5506: A Novel Approach to Protect Muscle in Duchenne Muscular Dystrophy

Joanne M Donovan, MD PhD
Chief Medical Officer
Edgewise Therapeutics

PPMD Connect Conference 2022
Forward-Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise’s drug discovery platform; Edgewise’s product candidates and programs, including EDG-5506; the expected milestones and timing of such milestones for EDG-5506 including the expected timing of reporting of data for EDG-5506 and clinical trials; statements regarding the market opportunity for Edgewise’s product candidates; statements regarding Edgewise’s pipeline of product candidates and programs; and statements regarding Edgewise’s financial position including its liquidity. In some cases, you can identify forward-looking statements by terminology such as “estimate,” “intend,” “may,” “plan,” “potentially” “will” or the negative of these terms or other similar expressions.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: negative impacts of the COVID-19 pandemic on Edgewise’s operations, including clinical trials; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; Edgewise’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in Edgewise’s plans to develop and commercialize EDG-5506 or any other product candidates; the potential for clinical trials of EDG-5506 or any other product candidates to differ from preclinical, interim, preliminary, topline or expected results; Edgewise’s ability to enroll patients in its ongoing and future clinical trials; operating results and business generally; Edgewise’s ability to raise funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Edgewise’s reliance on third parties, contract manufacturers and contract research organizations; Edgewise’s ability to obtain and maintain intellectual property protection for its product candidates; risks associated with access to capital and credit markets; the loss of key scientific or management personnel; competition in the industry in which Edgewise operates; Edgewise’s ability to develop a proprietary drug discovery platform to build a pipeline of product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Edgewise files from time to time with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation.

This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

EDG-5506 is an investigational agent and is not approved in any territory
The Edgewise Approach:  *Protect susceptible muscle fibers*

Some muscle fibers are more susceptible to damage due to the lack of functional dystrophin.

We’ve made an investigational therapy, **EDG-5506** that is designed to protect these susceptible muscle fibers from damage.

In diseased animal models, **EDG-5506** protected susceptible muscle fibers and prevented long-term development of damage.
Dystrophin Protects Muscles from Stress During Contraction Rather than Powering Contraction

The role of dystrophin is to connect parallel muscle fibers to distribute force across muscle during contraction.
Mechanical Stress Damages Dystrophic Muscle

When dystrophin is lacking, the mechanical stress that occurs during muscle contraction damages the muscle, leading to replacement with fat and fibrotic tissue and ultimately, loss of function.

Unchecked damage leads to fibrosis and functional decline.
Myosin Modulation: An Approach to Prevent Mechanical Stress when Dystrophin is Absent

EDG-5506 was designed to protect muscle by modulating myosin, a contractile protein in the fast muscle fibers that are damaged early and to a greater extent in Duchenne and Becker.

Decreased stress allows muscle to function without damage occurring
EDG-5506 Protects Dystrophic Mouse Muscle

Dystrophic mouse muscle is damaged during contraction

EDG-5506 protects dystrophic mouse muscle during contraction

Contraction leads to visible changes...

With EDG-5506, contractions don’t cause these changes
Injured Muscles Release Muscle Protein Biomarkers

Multiple muscle proteins enter the bloodstream and can be measured as biomarkers:

- Creatine Kinase
- Myoglobin
- Fast Troponin
- Many other muscle proteins
EDG-5506 Phase 1 Trial in Unaffected Adults and Those with Becker Muscular Dystrophy

What do we know about side effects?
- When dosed for two weeks, EDG-5506 was well-tolerated

How is EDG-5506 given?
- EDG-5506 can be taken as an oral tablet once a day that is absorbed well with or without food

Does it get to the muscle?
- EDG-5506 is highly concentrated in muscle compared to the bloodstream, which tells us that it is getting to where it needs to be to protect the muscle
Rapid Decrease in Biomarkers of Muscle Damage in Participants with Becker Muscular Dystrophy Treated with EDG-5506

**Creatine Kinase**

- Before Treatment
- On 2 Weeks of Treatment

**Fast Skeletal Muscle Troponin I**

- Before Treatment
- On 2 Weeks of Treatment

-71%  -83%
BMD and DMD are Related Dystrophinopathies

Spectrum of Severity Across Dystrophinopathies

BMD and DMD represent a continuum of the same disease. Edgewise’s approach aims to treat across the disease spectrum, regardless of dystrophin mutation.

References: Waddell LB et. al., Neurology Genetics, 2021; Brandsema JF and Darras BT, 2020
EDG-5506 is Being Developed for Becker and Duchenne Muscular Dystrophy

- Taken orally, intended to preserve and improve function in Becker and Duchenne patients with any mutation
- Goal to prevent damage to muscle by protecting the most susceptible fast muscle fibers
- Potential to be used alone or in combination with other therapeutic approaches for dystrophinopathies
- Designed to stop the damage where it begins
EDG-5506 Clinical Trials Ongoing and in Planning

• A 12-month open-label study is ongoing, including adults with Becker who were in the Phase 1 trial (NCT05160415)

• A natural history study of those with Becker has begun (ages 8 to 65) (NCT05257473)

• A study in ambulatory adolescent and adult males with Becker is planned to start in the first half of 2022 (ages 12+) (NCT05291091)

• An initial study in ambulatory boys with Duchenne is planned to start in the second half of 2022
Initial Phase 2 Study in Boys with Duchenne

• Planned to start in second half of 2022

• Population:
  — 4 to 9 years old, inclusive
  — Confirmed mutation in dystrophin gene with characteristic phenotype
  — Ambulatory
  — On stable dose of corticosteroids

• Design: 3-month placebo-controlled, followed by 9-month open-label

• Endpoints:
  — Safety, pharmacokinetics and biomarkers at 3 months
  — Functional assessments collected for longer term information
THANK YOU!